Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer
Top Cited Papers
Open Access
- 20 May 2014
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 146 (1), 15-24
- https://doi.org/10.1007/s10549-014-2988-5
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 ExpressionClinical Cancer Research, 2004
- Vaccine and antibody-directed T cell tumour immunotherapyBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2004
- B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.2003
- Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responsesEuropean Journal of Immunology, 2003
- Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockadeProceedings of the National Academy of Sciences of the United States of America, 2002
- Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast AdenocarcinomaThe Journal of Immunology, 2002
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasionNature Medicine, 2002
- Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughputin situ studiesThe Journal of Pathology, 2001
- PD-L2 is a second ligand for PD-1 and inhibits T cell activationNature Immunology, 2001
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte ActivationThe Journal of Experimental Medicine, 2000